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Summary.-An antiserum to methotrexate has been produced in a sheep against a
conjugate of ovalbumin and methotrexate (MTX) prepared using a water-soluble
carbodiimide. The antibodies produced were specific for substances containing the
2,4-diamino pteridine structure. Naturally occurring folates did not interfere with the
assay. A radioimmunoassay has been developed using this antiserum, which can be
used to measure MTX concentrations of less than 1 ng/ml in biological samples
without prior extraction. The concentrations of MTX in the blood and urine of
patients following a single i.v. bolus injection and following oral administration ofthe
drug have been measured. The published radioimmunoassays for MTX have been
compared.
THE antifolate drug methotrexate
(MTX) is extensively used in the treat-
ment of various forms of neoplastic
disease. The great improvement in anti-
tumour therapy achieved with it in
recent years has resulted not only from
increased clinical experience, but also
from a knowledge of the pharmaco-
kinetics of the drug (Henderson et al.,
1965a; Henderson, Adamson and Oliverio,
1965b; Huffman et al., 1973; Bischoff et
al., 1971; Dedrick, Bischoff and Zaharteo,
1970). The value of measuring the con-
centration of MTX in various body fluids
during treatment has recently been shown
by a number of workers (Bleyer, Chabner,
and Ommaya, 1973; Freeman-Narrod et
al., 1975; Frei et al., 1975; Shapiro,
Young and Mehla, 1975). The lack of
convenient, sensitive and specific methods
for measuring MTX is one reason why
widespread monitoring of its concentra-
tion in blood is not carried out more
often. Conventional assay techniques for
the measurement of MTX have been
available for a number of years (Freeman,
1957; Kinkade, V7ogler and Dayton, 1974;
Rothenberg, 1965; Werkheiser, 1961;
Arons et al., 1975; Fountain et al., 1953)
but are not generally specific or sensitive
enough to be suitable for clinical use.
Recently radioimmunoassays (RIA)
have been developed for MTX (Bohuon,
Duprey and Boudene, 1974; Levine and
Powers, 1974; Raso and Schreiber, 1975;
Hendel, Sarek and Hvidberg, 1976; Loe-
ffler, Blum and Nelson, 1976). These are
eminently suitable both for pharmaco-
kinetic studies and blood drug-level moni-
toring since, besides being fairly specific,
they are sensitive enough to measure
the drug in small volumes of sample
without prior extraction, and sufficiently
easy to perform for large numbers of
specimens to be processed rapidly at a
time.
This paper describes the development
of a sensitive rapid RIA for MTX using
Dextran-coated charcoal for phase separa-
tion, which is quick to perform and as
sensitive or more sensitive than previously
published techniques. Two clinical applica-
tions of the assay are illustrated and the
method, especially its specificity, is com-
pared with previously published radio-
immunoassays.RADIOIMMUNOASSAY FOR METHOTREXATE
MATERIALS AND METHODS
Chemicals.-MTX, aminopterin, 4-amino-
N10-methyl pteroic acid, N10-methyl folic
acid and 2,4-diamino-6-methylpteridine were
kindly supplied by Lederle Laboratories.
Biological 7-hydroxy MTX was a generous
gift from Dr A. Jacobs, NIH, Bethesda.
[3H]-MTX (TRK 224) was obtained from
the Radiochemical Centre, Amersham. Folic
acid and its analogues, ethyl (dimethyl
amino propyl)-ycarbodiimide (EDC), and
Norit A charcoal were purchased from
Sigma Chemicals Ltd, Dextran T-70 from
Pharmacia Ltd, and BCG vaccine from
Glaxo. All other chemicals and solvents
were obtained from BDH Chemicals Ltd.
Serum and urine samples from patients
receiving MTX w,ere supplied by Dr W. F.
White, St Luke's Hospital, Guildford, and
Dr H. E. M. Kay, The Royal Marsden
Hospital, Sutton, Surrey.
Production of immunogen. The conjugate
MTX-ovalbumin w-as prepared following
the method of Jaton and Ungar-Waron
(1967). Ovalbumin (225 mg; 5 ,umol), MTX
(55 mg; 120 umol) and EDC (23 mg; 120
,umol) were dissolved in 20 ml 0-05 M sodium
bicarbonate, pH 8-7, and allowed to stand
at room temperature for 18 h. The conjugate
was dialysed against 2 x 1-litre changes of
sodium bicarbonate solution and one of
distilled water, and lyophilized under vacuum.
The amount of MTX coupled to the protein
was determined by absorbance measurements
at 389 nm and calculated to be 4 mol MTX
per mol ovalbumin.
Iminmunization procedure.-Two New Zea-
land white rabbits were immunized with
1 mg conjugate in 0 5 ml sterile saline
emulsified with 1 ml complete Freund's
adjuvant, followed at weekly intervals with
3 x 0 5 mg conjugate in 0 5 ml sterile saline
emulsified with 1 ml Marcol 52 adjuvant
(Robinson, Morris and Marks, 1975). The
rabbits were bled from the marginal ear
vein 10 days after the last injection and at
monthly intervals thereafter.
Two sheep were immunized into 6 i.m.
sites in the legs with 5 mg MTX-ovalbumin
and 2 mg BCG vaccine in 1 ml sterile saline
emulsified with 2 ml Marcol 52 adjuvant.
One month later, 2 mg of the conjugate
was injected in the same way. Blood was
collected from the jugular vein 10 days after
each injection and monthly thereafter. The
blood was allowed to clot and serum separated
and stored at 4°C with the addition of
0l1% sodium azide.
Radioimnmnunoassay procedure.-The buffer
used throughout the procedure was 0 05 M
phosphate, 0-1 M NaCl, pH 7-4, containing
040o0 gelatin. The protocol for both anti-
serum dilution curves and for standard
curves is shown in Table I. OxfordR dis-
pensers or a Compu-petR (Warner Diag-
nostics Ltd) were used for dilutions and
additions. The amount of antiserum used
for establishing standard curves was deter-
mined by antiserum dilution curves, and
was that dilution which bound 5000 of
the added label. Tritiated MTX (10 Ci/mmol)
was stored at 4°C as a stock concentration
of 1 nm in 2% NaHCO3. This solution was
diluted with buffer, 1: 100, immediately
before use, so that 1 pmol (454 pg) [3H]-MTX
was added per tube. A solution of MTX
(10 ng/ml: 22 nM) was lyophilized in 2-ml
aliquots. An aliquot was reconstituted for
each assay and diluted to give the appro-
priate standards. Three or 4 10-fold dilutions
of each sample were prepared and the MTX
concentration at each dilution measured
in duplicate. Dextran-coated charcoal (DCC)
was prepared by mixing overnight at 4°C
a 25 g/l suspension of charcoal (Norit A) with
an equal volume (200ml) ofa2-5g/l suspension
of Dextran T-70. The fines were removed by
centrifugation and the DCC resuspended in
400 ml of buffer and stored at 4°C.
The reagents were added in the order
indicated in Table I to LP3 plastic tubes
(Luckham Ltd) the contents mixed and
allow-ed to stand at room temperature for
50 min followed by 10 min in iced water.
DCC was added, the tubes were mixed again
and allowed to stand for a further 10 min.
They were then centrifuged at 2500 rev/min
for 5 min. A 200-1I aliquot of supernatant
was taken from each tube for scintillation
counting in an LKB Ultrobeta or a Packard
Tricarb (2425) liquid scintillation counter.
RESULTS
Antiserum production
The MTX-ovalbumin conjugate was
immunogenic in the 4 animals immunized
with it. Preimmunization sera did not
bind [3H]-MTX specifically, and non-
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specific binding was always less than
100% of the total count added.
Antisera, obtained from two immunized
rabbits (G/R/45 and G/R/12) 10 days
after a total of 2-5 mg conjugate injected
over a period of 1 month, could be used in
the assay at a final dilution of 1: 9000
and 1: 1]2,000 respectively.
Ten days after the initial injection of
5 mg conjugate into the two sheep,
antisera obtained from them could be
diluted 1: 15,000 (HP/S/3 IA) and
1: 3500 (HP/S/7 IA) to obtain 5000
binding of [31H]-MTX. When boosted
with a further 2 mg conjugate, the anti-
body titres increased to 1 : 18,000 (HP/S/3
llA) and 1: 7200 (HP/S/7 llA) respect-
ively. Antiserum HP/S/3 1IA, which
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FIG. ]. The inhibition of [3H]-MTX-binding
by increasing amounts of MTX. Final
dilution of antiserum HP/S/3 was
1 : 18,000. 1 0 pmol [3H]-MTX was added
to each tube. Maximum binding in the
presence of excess antibody was 69 50
of total count added. Results from double
dilution of serum sample known to contain
MTX (El).
was available in large quantities, was
used for the remainder of the work
described here.
Radioimmnnoassay
The displacement of [3H]-MTX from
antibody sites by MTX standard is shown
in Fig. 1. The results are expressed as a
percentage of the maximum bound (i.e.
the amount of [3H]-AITX bound in the
presence of excess antibody). The addition
of 50 ,ul of normal human serum to the
standard curve did not alter its shape or
the percentage binding. The results of
a serum sample which was known to
contain MTX were superimposable on
the standard curve (Fig. 1). The sensitivity
of the assay calculated by the method
of Albano and Ekins (1-970) was 450
pg/ml. The average avidity of the anti-
serum for MTX was calculated by a
Scatchard plot of the data of the standard
curve, and was 5-13 x 109 I/mol at an
antibody binding-site concentration of
8-5 x 10-9 mol/l.
A suitable incubation time for antigen-
antibody reaction was determined by
setting up a series of zero tubes (Table I)
and allowing them to stand for up to
10 min before placing them in the iced
water for 10 min. Binding of [3H]-MTX
to antibody was extremely rapid, since
3600 of the total counts added were
bound within 1 min and reached a maxi-
mum of 44% total counts bound at
30 min. The 10-min incubation with DCC
could be increased to 20 min without
stripping any of the antibody-bound
[3H]-MTX although if the time of contact
was increased to 30 min
- 10% of
antibody-bound [3H]-MTX was removed.
The times chosen for the routine assav
(Table I) were, therefore, selected for
convenience.
MTX added to serum, uirine and CSF
could be recovered quantitatively without
prior treatment or extraction of the
sample (Table II). Normal pooled sera
to which MTX was added to give concen-
trations of 100 ng/ml (0.22 ,uM) and 1000
ng/ml (2.2 juM) were assayed on different
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TABLE I. Procedure for RIA of MTX
Volume of reagents added (pl)
o~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~----
Reagent
Diluent buffer
Standlard or sample
Antiserum
[3H]-MTX (1O nM)
DCC (25% )
Total
counts
tube
600
100
Non-specific
binding
tube
500
100
Maximum Zero tube
binding or antiserum
tube dilultion curve
400
500
100
100
100
Incubate 50 min at RT followe(d by 10 min at 4°(
100 100 100
Leave for 10 min.
Centrifuge and couInt 200 pl supernatant
Standard
or sample
tube
300
100
100
100
100
TABLE II.-The Recovery of MTX
Amount of MTX
Amount of MTX recovered
added (ng/ml +CV)
(ng/ml) n=4
Serum 100 106-0+10-6
Urine 100 1048 8 11*4
CSF Ill 116 0±11 0
occasions over a period of one month.
Mean values of 105 ng/ml (n- 10, coeffi-
cient of variance 5-8%) and 1019ng/ml
(n - 6, coefficient of variance 93%o)
were obtained. Intra-assay variation for
a sample of mean value 1044 ng/ml
(2-3 juM) was 2% (n 6). A mixed pool
of serum samples collected from patients
receiving MTX was assayed 15 times in
2 weeks, and had a coefficient of variance
of 96% (mean value 948 ng/ml: 241
To determine whether only free MTX
or total MTX (i.e. free MTX plus that
bound by plasma proteins) was being
measured by the radioimmunoassay, a
dialysis experiment was carried out.
1 ml each of 7 serum samples of known
MTX concentration (measured by RIA)
San
I
I
z
p
r
was dialysed in smallperspex cells, through
Visking membrane, until equilibrium of
free drug across the membrane (as ascer-
tained by the use of [3H]-MTX was
achieved (-18 h). The serum samples
were dialysed against 1 ml of 0 05 M
phosphate buffer at room temperature,
and the concentration of MTX on
each side of the dialysis membrane
measured by RIA (Table III). The per-
centage of the MTX unbound to plasma
proteins varied between 42% and 7300
of the total MTX, and the total amount
of drug recovered following the dialysis
varied from 66 to 100%. It is interesting
to note that serum sample Nos. 4, 5, 6
and 7 were obtained from a patient
receiving 1-5 g/day of salicylate by mouth
in addition to the MTX treatment.
Antiserum HP/S/3 1lA was assessed
for its cross-reactivity by replacing stand-
ard MTX in the assay with analogues of
MTX at concentrations up to 100 [tg/ml.
Results obtained with structurally related
compounds are shown in Table IV. The
addition to the assay tubes of 10 jig
TABLE III. Measurement ofFree and Plasma-bound MTX
MTX conc. MTX conc. of %
MTX conc. in dialysate dialysed sample free 00 recox
nple (K.g/ml) (GLg/ml) (Kg/ml) MTX of MT
1 25-70 5-480 42-6
2 2-39 2-390 41-5
3 0-171 0 043 0-107 50 3 87-7
4 9-800 2-710 3-75 55-3* 65-s
5 10-500 3-170 7-30 60-4* 99.7
6 9-750 2-900 4-60 59.5* 76-9
7 0-020 0-007 0-010 73-1* 87-3
very rx
* Samples were obtained from a patient receiving 1 5 g salicylate by mouth daily.
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TABLE IV. The Inhibition of Antiserum-
binding of [3H]MTX by MTX and
Structurally Related Compounds
Methotrexate
4-amino-NI0-methyl
pteroic acid
Aminopterin
7-hydroxy MTX
2,4-diamino-6-methyl
pteridine
N10-methyl-folic acid
Folic acid, dihydrofolic
acid, tetrahydrofolic
acid, folinic acid (Leai-
covorin), p-amino-ben-
zoic acid, glutamic aciel
Amount
require(I
for 50%
inhibition
(ng)
0 65
21
70cross-
reactivity
100-0
31 -0
:3-4 19-10
270 0-23
560 0-12
2250
> 10000
The %o cross-reactivity is expressedl
centage of the amount of MTX required
the same inhibition of binding.
of each of the compounds sh
Table V failed to displace the ai
bound [3H]-MTX.
Measurement of MTX in clinical,,
The disappearance of MTX fi
serum of two patients given 200
TABLE V.-Unrelated Cornpounds Exhi-
biting No Reaction uith the Antiserum
(1 ) ug of each compoundt was a(l(le(d to
the assay tube)
Vinblastilne -Nortriptyline
Fluorouracil Ephedrine
Cytosine arabinoside Tetracycline
Adriamycin Nicotine
Mercaptopurinle Amphetamine
Bleomycin Prednisolone
Codeine Prochlorperazinie
Diazepam Chlorpromazine
Salicylate Sodium barbital
Digoxin
0-03 <0-0065 300 mg MTX as an i.v. bolus injection
at Time 0 is shown in Fig. 2a. The
urinary excretion of MTX in the same
two patients is shown in Fig. 2b. In the
patient given 200 mg MTX, 80% of the
as a per- dose was excreted within 25 h, and in
to cause the other patient 900,% was excreted
within 24 h.
lown in The absorption of the drug following
ntibody- oral administration of 20 mg MTX is
illustrated in 3 patients with acute
lymphoblastic leukaemia (Fig. 3). The
samples urinary excretion of MTX in the first
rom the 5 h after drug administration was 50-2,
mg and 44-2 and 705%o of the dose respectively.
0.1
(a)
40
20
(b)
0 5 10 15 20 25 0 5 10 15 20 25
TIME (h) TIME (h)
FIG. 2. (a) The disappearance of MTX from the bloocd following a single i.v. bolus injection an(d
(b) its urinary excretion. 0 Patient A, 200 mg MTX; 80% excretion in 25 h. 0 Patient B, 300 mg
MTX; 90% excretion in 24 h.
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conjugates made with bovine serum al-
bumin, ovalbumin, and thyroglobulin as
carrier proteins, and of varying degrees
of derivatisation (4-20 mol MTX/mol pro-
tein) were also immunogenic in l00%ofthe
animals immunized with them 14 rabbits
and 6 sheep. Antisera from the majority
of these animals, though suitable for RIA
procedures, were not further developed.
The reason for the high immunogenicity
of MTX conjugates is not known.
The antiserum chosen for development
of an RIA for MTX was available in
large quantities and had a high titre.
The sheep from which the serum was
obtained has been boosted several times
since the material described in this paper
was obtained, and has yielded antisera
ofsimilar or improved binding capacity for
[3H]-MTX.
Naturally occurring folates and folinic
acid failed to displace [3H]-MTX bound
to antibodies, even at concentrations
104 times greater than that of MTX,
permitting measurement of MTX to be
made even in the presence of artificially
ipai!lonflQ LOIIC1 f <stOQ {D a liirin(r fnalinio_
50 100 150 200
TIMIE (min)
FiG. 3.-The concentration of MTX inI
following 20 mg MTX orally. Pati
50 2%; Patlent D, 44 o2%, ancl Pat
70 50 MTX excreted in 5 h.
DISCUSSION
The conjugate MTX-ovalbumi
to be extremely immunogeni
4 animals immunized with i
1-aiseu levels o1 1U1tULes ke-.Y. t1t11-I11g IUIIIIIU-
250 300 acid rescue).
The main antigenic characteristics of
ient c, MTX appear to be the amino group at
jent E, position 4 and the N10 methyl group
(Fig. 4). The antiserum HP/S/3 I IA
appears to be directed at structures
containing the 2,4-diamino substituted
in proved pteridine ring, since all the substances
c in all tested which possessed this structure
it. MTX cross-reacted with it to a greater or lesser
Nil, 0'1
N N C2--N'0 /NH-
2 7
HIN/"N N ClI 2BA
COOH
-CH
CH2
COOH
FIG. 4. The structure of AITX. 4-amino-N10-methyl pteroic acid ancl 2,4-diamino-6-methyl pteridine
result from cleavage at A an(i B respectively.
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extent. The whole MTX molecule seemed
to be necessary for fuLll antigenic expres-
sion, however, since removal of the
glutamate residue (which did not itself
inhibit the [3H]-MTX binding to antibody)
to produce 4-amino-N10-methVl pteroic
acid reduced cross-reactivity to 30%o
of the parent compound, and further
removal of the para-amino benzoic acid
residue to produce 2,4-diamino-6-methyl
pteridine virtually abolished its abilitv
to displace [3H]-AITX.
The importance of the N10-methyl
group in the antigen-antibody reaction
is indicated by the relatively low (19%)
cross-reactivity between the aintiserum
and aminopterin in which the N10 group
is absent, and its greater cross-reactivity
with N10-methvl folic acid than with
folic acid itself.
Modification of the actual pteridine
nucleus, such as occurs in 7-hydroxy
MTX (an important metabolite of MTX
during high-dosage treatment regimes
(Jacobs et al., 1976)) reduced antibody-
binding very markedly. It may even
have abolished it, since the reference
preparation of 7-OH-MTX we had avail-
able was contaminated with small amounts
of MTX, as shown by column chromato-
graphy on DEAE cellulose.
Both 4-amino-N10-methyl pteroic acid
and 2,4-diamino-6-methyl pteridine have
been identified in the urine and faeces of
several different species of animal fol-
lowing MTX administration. Their pre-
sence is thought more likely to be due to
bacterial cleavage during enterohepatic
circulation of the drug (Johns and Vale-
rino, 1971; Valerino, 1972) than to
endogenous metabolism. In man, 4-amino-
N10-methyl pteroic acid is found in the
urine 24-96 h after the administration
of MTX, in amounts up to 30%o of the
total dose MTX given. It is, however,
not detectable at all during the first
24 h (Huffman et al., 1973). Because of
the cross-reactivity of4-amino-N10-methyl
pteroic acid in the MTX RIA of urine,
samples collected more than 24 h after
a single dose of MTX, or at any time
during long-term MTX treatment, will
give falsely high results for urinary MTX
excretion. This potentially important
cause of confusion has not been ade-
quately recognized in the past, but is
amenable to investigation by chromato-
graphic separation of urinarv MTX and
its metabolites before RIA. Work along
these lines is currently in progress in our
laboratory.
The radioimmunoassay described in
this paper has proved reliable and repro-
ducible in routine use for monitoring
MTX concentrations duriing treatment
of neoplastic disease, and has an inter-
assay variation of 5-10%. Intra-assavT
variation is as low as 20g. Because of the
high avidity of the antiserum, a short
incubation time is all t,hat is required,
and this can be shortened or lengthened
slightly to fit into the laboratory routine
should this be desired. Moreover, timing
of the various stages is less critical than
with assays using less avid antisera, and
this is useful when large numbers of
specimens are being analysed. The only
limitation on the number of samples
assayed at any one time is the capacity
of the refrigerated centrifuge. Up to 20
samples, each set up at 3 or 4 different
(lilutions to span a wide range of concen-
trations, can be assay,ed in a single batch,
so that the results become available
within 24 h. The method is especially
well suiited for routine monitoring of
blood levels when it is necessary to
know for how long folinic acid "rescue"
should be continued. The avidity of the
antiserum is sufficiently high to overcome
the binding of MTX. to plasma proteins,
so that preliminary extraction of MTX is
unnecessary.
The sensitivity of the present assay is
such that it, permits plasma MTX con-
centrations to be measured for extended
periods after its administration, as well
as in fluids such as CSF, in which the
drug is generally present in much smaller
concentrations than in blood. The high
sensitivity of the assay is an advantage
during pharmacokinetic studies, since only
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small sample volumes are required for
analysis. It does, however, bring its ownl
problems, in so far as multiple dilutions
are often required to bring the MTX
concentration within the range of the
standard curve.
Table VI compares the different RIA
methods for MTX published in the litera-
ture to date. Although a wide variety
of carrier proteins has been used to
render MTX immunogenic, it is quite
clear from the information available that
all the conjugates are very immunogenic.
The least immunogenic conjugate so far
described was one in which poly-L-lysine
was used (Loeffler et al., 1976). The
degree of haptenic derivatisation of the
immunogenic conjugate varied from 4 to
85 mol MTX per mol of carrier protein in
published accounts, without any dis-
cernible effect upon the resultant immuno-
genicity. This accords with our owIn
experience, which indicates that in the
case of MTX, the degree of derivatisation
had little effect upon immunogenicity,
unlike most other haptens which have
been shown to have an optimum im-
munogenicity at 15-30 substitutions per
mol of protein (Robinson et al., 1975).
Three different species have been used
to raise antibodies for use in MTX RIA.
The methods of immunization chosen
have been intradermal and/or subcu-
taneous in all but the present study, in
which the intramuscular route was em-
ployed. The final dilution of antibody
used in the published assays varied from
1: 120 to 1: 18,000, but antibody avidity
was reported in only two cases. The
methods used to calculate avidity were
different in the two cases, which might
possibly account for the I 00-fold difference
between them. Alternatively, the differ-
ences might be real and be reflected in the
different sensitivity of the resultant as-
says.
The specificities of the antisera ob-
tained were in general very similar. All
the antisera were highly specific with
regard to folic acid and its analogues,
thereby permitting measurement of MTX
in the presence of folates, even when
these were deliberately elevated.
Cross-reactions of the antisera with
known matabolites of MTX were not
always reported. This is unfortunate
since, for reasons already given, it is
important to know which of the meta-
bolites interfere with the assay.
Tritiated MTX was used as label in
all the published methods, and the amount
used was generally less than 1 ng [3H]-
MTX per assay tube. Assays using
gamma emitting 1251 (Diagnostic Bio-
chemistry Inc.) or 75Se as labels (un-
published observations) are either avail-
able commercially or at an a dvanced
stage of development, but details of the
characteristics of these assays are not
vet available. The sensitivity of all the
published assays is similar and more
than adequate for almost every clinical
and experimental purpose.
All the published methods differ in
detail amongst themselves but true com-
parisons of their reliability, accuracy,
precision, cost-effectiveness and clinical
usefulness can only be made by com-
paring the results obtained on identical
samples distributed through an inter-
national quality control scheme, such as
those now available for other drugs and
compounds of biological interest.
We wish tro thaink the Leukaemia
Research Fund for generous financial
support.
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